Leqembi

Generic Name/API: Lecanemab
Manufacturer: Eisai
Packaging: Injection form
Storage: Store in a dry place at 20°C to 25°C
Dosage: 10 mg/kg as an intravenous infusion
Strength: 500 mg/5 mL / 200 mg/2 mL solution in a single-dose vial
Indication: Leqembi, or Lecanemab, is a newly approved Alzeihmer’s drug.
No Indian generic option is available.
 
?>

About Lecanemab

Lecanemab is a prescribed medicine to treat Alzheimer’s disease. Treatment with Leqembi should be started in individuals with moderate cognitive impairment or mild dementia, the population treated in clinical studies. There are no data on the safety or efficacy of starting therapy at earlier or later stages of the disease than was evaluated. This indication was granted expedited approval based on decreased amyloid beta plaques in Leqembi-treated individuals. Continued approval for this indication may be predicated on clinical benefit being demonstrated in a confirmatory study.


Strength

Injection: 500 mg/5 mL solution; 200 mg/2 mL solution.


Recommended Dosage:

The recommended dosage is 10 mg/kg, which must be diluted before being provided as an intravenous infusion over one hour once every two weeks.

Important: If patients experience any adverse reactions from the Lecanemab treatment, they must consult their treating doctor. 


Warnings & Precautions

  • During the first 14 weeks of Leqembi medication, increased clinical monitoring of ARIA (Amyloid Related Imaging Abnormalities) is advised. Apolipoprotein E 4 homozygotes had a higher risk of ARIA, including symptomatic ARIA, than heterozygotes or noncarriers. A clinical assessment, including MRI scanning, should be done if a patient exhibits symptoms indicative of ARIA.
  • The infusion rate may be lowered or withdrawn, and appropriate treatment may be delivered as clinically required (Infusion-Related Reactions). Before subsequent dosage, consider pre-medication with antihistamines, nonsteroidal anti-inflammatory medications, or corticosteroids.

Common Lecanemab Side Effects

  • Infusion-related reactions
  • Headache
  • ARIA-edema

Storage and Handling

To protect them from light, store in a refrigerator at 2°C to 8°C.

We follow a four-step process to procure the medicines:

  1. Inquiry about the medicines: You submit a request for information about the medications you require using our portal, and we process your data. Within 24 hours, a Named Access Program Support member will contact you and provide you with all the assistance you need. 
  2. Verification Process: As we assist patients in finding medications yet to be approved and readily available in their home countries, Sansfro must confirm the availability and approval of the medicines they need. We also check the patient’s prescription and medical information. 
  3. Sourcing the Medicine: After completing the verification process, our staff will contact our vast network of suppliers to find your medicine. Following the procedure, our team gets the best rates of the medication for you and ensures processing. 
  4. Safe Delivery: We will set up the consignment’s safe delivery after the final quote is approved. Additionally, our logistics experts can help you track your consignment. The Named Access Program industry has a large number of unauthorized channels. We do so by adhering to the Standard Operating Procedures to provide the medications safely and legally. 

When importing medication, we will need the following documents from the patient:

  1. A valid prescription copy.
  2. An identity proof document.
  3. Details of the attending healthcare professional.
  4. A current address.

Once we have all these documents, the Sansfro team will initiate the application process for an import license. This license is essential to ensure that we can obtain the necessary medication once it receives government approval.

No news found.

About Sansfro

Sansfro is committed to bridging the healthcare gap. Our purpose is to bring hope and healing to patients suffering from rare diseases by linking them with life-saving treatments through our Named Patient Program. Join us in our quest for a better and healthier world.

Know More...

FAQ'S

Is there any approved medicine for Alzheimer’s?

Yes, Leqembi is the newly approved Alzeihmer’s drug. 

Are there any side effects of Leqembi?

The common Leqembi side effects are infusion-related reactions, headache, and ARIA-edema.

Where can I find the newly approved Alzeihmer’s drug?

Connect with the patient support team at Sansfro to learn more about ordering Leqembi.

What is the price of Leqembi in India?

Leqembi price in India depends on the product requirement. Request more details by contacting our Patient Support Team at ‎(+91) 93157 05373 or help@sansfro.com.  

Dr Anchal Aryan

Medical counselor

Patient Support Head Detail

Dr Anchal Aryan

Medical counselor

COTACT US NOW

Patient Stories

Great Customer support
Invimeds Health boasts an exceptional team that consistently provides excellent customer service. We extend our gratitude to Sachin.
Aamir Hussain
Leqembi for Grand father
Invimeds helped me for providing my grand father LEQEMBI for Alzheimers in far flung area of Uttarkhand.
Shivam Pandit
Thankyou Invimeds
Thank you Invimeds team for providing Zejula for my grand mother at earliest. This has helped us a lot to go ahead with her cancer treatment.
Satrudhan Shukla

Word Wide Delivery:

India, Andorra, Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe, Afghanistan, Albania, Algeria, American Samoa, Angola, Anguilla, Antarctica, etc.

×